Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. (2020)

First Author: Tallantyre EC
Attributed to:  MRC Centre for Neuropsychiatric Genetics and Genomics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.msard.2020.102056

PubMed Identifier: 32353753

Publication URI: http://europepmc.org/abstract/MED/32353753

Type: Journal Article/Review

Volume: 42

Parent Publication: Multiple sclerosis and related disorders

ISSN: 2211-0348